Contact us

877-469-1TRM
424-208-8866

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine or Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (tnAcity)

A Phase 2/3, Multi-center, Open-label, Randomized Study of Weekly Nab-paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to the Combination of Gemcitabine and Carboplatin, as First-line Treatment in Female Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Triple Negative Metastatic Breast Cancer Patients nab-Paclitaxel II/III Temporarily Closed to Accural